PLRX
PLIANT THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.85
−1.03%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.86
From 52W high−52.68%
Volume204987.00
Market cap$52.75M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$0.86
From 52W high
−52.68%
Volume
204987.00
Market cap
$52.75M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.9x
P/E (TTM)
—
RSI (14)
36.6
MomentumView details →
1D Return
−1.03%
YTD Return
−30.11%
SummaryUpdated Jun 1, 2026
Pliant Therapeutics, Inc. (NASDAQ:PLRX) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in South San Francisco, California. The company went public in June 2020 and focuses on discovering, developing, and commercializing novel therapies for the treatment of fibrosis and related diseases. Pliant operates in the highly specialized field of integrin biology, targeting specific cellular receptors that play crucial roles in tissue scarring and fibrotic diseases. The company is currently advancing multiple drug candidates through clinical trials, with its lead program targeting conditions such as idiopathic pulmonary fibrosis and primary sclerosing cholangitis.
Similar companies
Latest newsMore news →
PLIANT THERAPEUTICS, INC. announced that a presentation on its ongoing FORTIFY Phase 1b trial of PLN-101095 is scheduled for the ESMO Congress 2026 in Madrid from October 23 to 27, 2026.16d agoPliant Therapeutics appointed Flavia Borellini, Ph.D. and Robert Iannone, M.D. as seasoned oncology drug development leaders.85d agoPliant Therapeutics appointed Flavia Borellini and Robert Iannone to its board of directors.114d ago